Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

148 results about "Genetic Alteration" patented technology

High throughput multiplex DNA sequence amplifications

InactiveUS20060281105A1Efficient and simultaneous amplificationMinimize formationMicrobiological testing/measurementBiological testingHigh throughput genotypingGenome scale
The present invention provides methods of designing PCR primers that allow the efficient and simultaneous amplification of a large number of different desired DNA fragments in a single multiplex PCR and minimize the formation of nonspecific extensions of undesired DNA fragments. The present invention allows a multiplex PCR to use at least 50 pairs of primers and produce at least 50 DNA fragments of interest. The present invention significantly broadens the application of multiplex PCR in the identification of multiple genes related to multifactorial diseases, the genome-scale detection of genetic alterations, the studies in large-scale pharmacogenetic reactions, the genotyping genetic polymorphism in a large population, the gene expression profiling in various samples, and high throughput genotyping technologies.
Owner:LI HONGHUA +1

Identification and use of circulating nucleic acid tumor markers

Methods for creating a selector of mutated genomic regions and for using the selector set to analyze genetic alterations in a cell-free nucleic acid sample are provided. The methods can be used to measure tumor-derived nucleic acids in a blood sample from a subject and thus to monitor the progression of disease in the subject. The methods can also be used for cancer screening, cancer diagnosis, cancer prognosis, and cancer therapy designation.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Genetic Alterations Useful For The Response Prediction of Malignant Neoplasia to Taxane-Based Medical Treatments

The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions.
Owner:SIEMENS HEALTHCARE DIAGNOSTICS GMBH

Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions

An improved method of nuclear transfer involving the transplantation of differentiated donor cell nuclei into enucleated oocytes of a species different from the donor cell is provided. The resultant nuclear transfer units are useful for the production of isogenic embryonic stem cells, in particular human isogenic embryonic or stem cells. These embryonic or stem-like cells are useful for producing desired differentiated cells and for introduction, removal or modification, of desired genes, e.g., at specific sites of the genome of such cells by homologous recombination. These cells, which may contain a heterologous gene, are especially useful in cell transplantation therapies and for in vitro study of cell differentiation. Also, methods for improving nuclear transfer efficiency by genetically altering donor cells to inhibit apoptosis, select for a specific cell cycle and / or enhance embryonic growth and development are provided.
Owner:ADVANCED CELL TECH INC

Yeast arrays, methods of making such arrays, and methods of analyzing such arrays

This patent describes a novel method of detecting genetic interactions in yeast. This method can also be used to screen for function of biological effectors on yeast. The method encompasses crossing yeast strains with genetic alterations to acquire double mutants. The phenotypes of these double mutants are then checked to detect genetic interactions between the double mutants. This method can be used to assign function to yeast genes and their viral, prokaryotic, and eukaryotic homologs, and aptamers. It can also be used to study yeast two hybrid interactions and to find genes that regulate certain yeast promoters.
Owner:BOONE CHARLES

Compositions and methods for genetic analysis of embryos

The present disclosure provides for compositions and methods for genetic analysis of embryos. Generally, the compositions and methods provide for the acquisition of an sample containing RNA from an embryo, genetic analysis involving various techniques such as sequencing-, hybridization- or amplification-based methods, and the detection of genetic alterations that may affect the health and quality of the embryo. In some cases, compositions and methods of this disclosure may provide information useful in the selection and monitoring of embryos for implantation into a female.
Owner:REPRODIVE GENETICS & TECH SOLUTIONS

Identification of genetic alterations that modulate drug sensitivity in cancer treatments

InactiveUS20080242622A1Improve efficiencyModulate cancer cells' sensitivity to an anti-cancer drugBiocideLibrary screeningCancer cellDrugs sensitivity
This invention features methods of identifying genetic alterations that can modulate cancer cells' sensitivity to an anti-cancer drug. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy.
Owner:COLD SPRING HARBOR LAB INC

Mutations of the PIK3CA gene in human cancers

Phosphatidylinositol 3-kinases (PI3Ks) are known to be important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in cancers, we analyzed the sequences of the P13K gene family and discovered that one family member, PIK3CA, is frequently mutated in cancers of the colon and other organs. The majority of mutations clustered near two positions within the P13K helical or kinase domains. PIK3CA represents one of the most highly mutated oncogenes yet identified in human cancers and is useful as a diagnostic and therapeutic target.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma

We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1

Orthotopic, controllable, and genetically tractable non-human animal model for cancer

This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations (e.g., in oncogenes and tumor suppressor genes) that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both, preferably by inducible, reversible, and / or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene, and by transplanting the resulting hepatocytes into a recipient non-human animal. The invention further provides a method to treat cancer involving cooperative interactions between a tumor cell senescence program and the innate immune system.
Owner:COLD SPRING HARBOR LAB INC

Volatile organic compounds for detecting cell dysplasia and genetic alterations associated with lung cancer

The present invention provides methods of identifying a genetic abnormality such as mutation in EGFR or KRAS or ALK which is associated with the management of lung cancer or diagnosing, prognosing or monitoring the treatment of pre-cancerous conditions of the lung, such as bronchial dysplasia or atypical alveolar hyperplasia (AAH), through the detection of at least one volatile organic compound indicative of these states.
Owner:UNIV OF COLORADO THE REGENTS OF +1

Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma

ActiveUS20110229479A1Increase and decrease and stable levelSugar derivativesMicrobiological testing/measurementGlioblastomaLower grade
We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1

Hormone responsive tissue culture system and uses thereof

The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media / culture conditions, these cells can be induced to differentiate.The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1

Salivary Mrna Profiling, Biomarkers and Related Methods and Kits of Parts

A method to detect a biomarker in saliva wherein the biomarker is an extracellular mRNA, comprises detecting the extracellular mRNA in the cell-free saliva; transcriptome analysis of saliva comprises detecting a transcriptome pattern in the cell-free saliva; a method to detect genetic alterations in an organ or in a gene in the organ by analyzing saliva, comprises detecting a transcriptome pattern and / or the mRNA profiling of the gene in cell-free saliva; a method to diagnose an oral or systemic pathology disease or disorder in a subject, comprises: detecting profile of a biomarker associated with the pathology disease or disorder, in particular mRNA and / or protein, in cell-free saliva and / or serum; kits comprising identifier for at least one biomarker for performing at least one of the methods; and use of salivary biomarker salivary and / or serum mRNAs as biomarkers for oral and / or systemic pathology, disease or disorder.
Owner:RGT UNIV OF CALIFORNIA

Integrated Analyses of Breast and Colorectal Cancers

Genome-wide analysis of copy number changes in breast and colorectal tumors used approaches that can reliably detect homozygous deletions and amplifications. The number of genes altered by major copy number changes—deletion of all copies or amplification of at least twelve copies per cell—averaged thirteen per tumor. These data were integrated with previous mutation analyses of the Reference Sequence genes in these same tumor types to identify genes and cellular pathways affected by both copy number changes and point alterations. Pathways enriched for genetic alterations include those controlling cell adhesion, intracellular signaling, DNA topological change, and cell cycle control. These analyses provide an integrated view of copy number and sequencing alterations on a genome-wide scale and identify genes and pathways that are useful for cancer diagnosis and therapy.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

ONCOGENOMICS-BASED RNAi SCREEN AND USE THEREOF TO IDENTIFY NOVEL TUMOR SUPPRESSORS

In some aspects, the invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal.The present invention also provides methods for identifying and validating tumor suppressor genes by screening pools of shRNAs that target genomic regions deleted in human cancers, such as human hepatocellular carcinomas. The present invention also provides validated tumor suppressor genes, and methods of inhibiting cell proliferation and / or tumor growth, for example by expression of such tumor suppressor genes.
Owner:COLD SPRING HARBOR LAB INC

Method for enhancing the nutritive value of plant extract

The present invention relates to a method for increasing the stability of endogenous proteins recovered from plant cells or plants. The preservation of endogenous proteins integrity of endogenous protein occurs by neutralizing proteolysis in crude extracts, particularly by the use of genetic alteration of plant cells or plants that express recombinant protease inhibitors or altered activity of specific target proteases.
Owner:UNIV LAVAL

Application of fluorescent in-situ hybridization polyclonal separating probe for renal carcinoma and kit thereof

The invention relates to application of a fluorescent in-situ hybridization polyclonal separating probe for renal carcinoma and a kit thereof. Clonal fragments used by the polyclonal separating probe provided by the invention are respectively a combination of RP11-416B14, CTD-2522M13 and CTD-2516D6, and a combination of CTD-2312C1, CTD-2248C21 and RP11-959H17. According to the invention, the defect that karyotype analysis can not be performed conventionally after tumor cells are subjected to cell culture until a mitotic phase in the prior art is overcome. The typical gene modification in Xp11.2 translocation / TFE3 gene fusion related renal carcinoma is detected by using the FISH technology, thereby diagnosing the tumor. The fluorescent in-situ hybridization polyclonal separating probe application is high in accuracy, high in specificity, high in success rate, strong in fluorescent signals and convenient to operate. The invention can be applied in paraffin sections, widens the scope of detection specimens, and greatly optimizes the diagnosis method of Xp11.2 translocation / TFE3 gene fusion related renal carcinoma.
Owner:THE AFFILIATED DRUM TOWER HOSPITAL MEDICAL SCHOOL OF NANJING UNIV

Development and use of a new orthotopic, genetically tractable non-human animal model for liver cancer

This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal.
Owner:COLD SPRING HARBOR LAB INC

Method for cloning animals with targetted genetic alterations by transfer of long-term cultured male or female somatic cell nuclei, comprising artificially-induced genetic alterations, to enucleated recipient cells

An improved method of nuclear transfer employing long-term cultured somatic cells as the donor cells and enucleated oocytes as the recipient cells to produce dividing cybrids. Such cybrids are useful for developing viable animals clones when nurtured in a suitable host environment.
Owner:GOVERNOR OF KAGOSHIMA PREFECTURE THE +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products